354 results about "Alcohol free" patented technology

A foamable composition, includes (1) about 6% to about 70% by weight of at least one organic carrier; (2) about 0.1% to about 5% by weight of at least one surface-active agent; (3) about 0.01% to about 5% by weight of at least one film forming agent; (4) water; and (5) about 3% to about 25% by weight of the total composition of at least one liquefied or compressed gas propellant. The composition is substantially alcohol free and is used in treating, alleviating or preventing a disorder.

The invention relates to an alcohol-free cosmetic or pharmaceutical foam carrier including water, a hydrophobic solvent, a surface-active agent and a gelling agent. The cosmetic or pharmaceutical foam carrier does not contain aliphatic alcohols, making it non-irritating and non-drying. The alcohol-free foam carrier is suitable for inclusion of both water-soluble and oil soluble pharmaceutical and cosmetic agents.

The invention relates to uses of an alcohol-free cosmetic or pharmaceutical foam carrier comprising water, a hydrophobic solvent, a foam adjuvant agent, a surface-active agent and a water gelling agent as a flame retardant or flame resistant foam. The hydrophobic solvent is preferably mineral oil; medium chain triglycerides; isopropyl myristearate or octyl dodecanol, silicone oil or vegetable oil or mixtures thereof. The cosmetic or pharmaceutical foam carrier does not contain aliphatic alcohols, also making it non-irritating and non-drying. The alcohol-free foam carrier is suitable for inclusion of both water-soluble and oil-soluble pharmaceutical and cosmetic agents.

A stable topical alcohol-free aerosol foam containing one or more keratolytic agents is provided. The foam-forming formulation is an emulsion which contains an HFA propellant and one or more keratolytic agents. The emulsion has an oil phase and an aqueous, i.e. water-containing, phase. The active agent(s) may be present in either phase of the emulsion or dispersed in the emulsion. The oil phase may consist at least in part of the HFA propellant. Either or both of the oil phase and the aqueous phase may contain one or more surfactants, emulsifiers, emulsion stabilizers, buffers, and/or other excipients. The foam is stable on the skin, for example, for at least 5 minutes at body temperature, preferably at least 20 minutes at body temperature, and disappears into the skin upon rubbing or after prolonged standing. In one embodiment, the formulation contains an HFA propellant which does not contain additional co-solvents or co-propellants. The formulations demonstrate reduced intensity of the odor and/or color associated with the keratolytic agent(s) as compared to conventional formulations containing keratolytic agents.

The invention relates to an alcohol-free cosmetic or pharmaceutical foam carrier comprising water, a surface-active agent a gelling agent and a combination of active agents, which creates, upon admixing, a eutectic mixture. The foam carrier further comprises active agents and excipients with therapeutic properties.

The invention relates to an alcohol-free cosmetic or pharmaceutical foam composition comprising water, a hydrophobic solvent, a surface-active agent, a gelling agent, an active component selected from the group of urea, hydroxy acid and a therapeutic enhancer and a propellant. The foam further comprises active agents and excipients with therapeutic properties having enhanced skin penetration.

The object of the present invention is to minimize the risks of dose dumping associated with the concomitant consumption of alcohol and certain modified-release pharmaceutical or dietetic forms. The invention relates to an oral form comprising microparticles of the reservoir type for the modified release of at least one active principle (AP), characterized in that it is resistant to immediate dumping of the dose of AP in the presence of alcohol. In particular, the oral form according to the invention is characterized in that the time taken to release 50% of the AP in an alcoholic solution is not reduced more than 3-fold relative to the time taken to release 50% of the AP in an alcohol-free aqueous medium. The form comprises an agent D, which is a pharmaceutically acceptable compound whose hydration or solvation rate or capacity is greater in an alcohol-free aqueous medium than in alcoholic solution

An alcohol-free, transdermal drug delivery composition administered via a metered spray drug delivery device is described herein. The non-occlusive transdermal drug delivery composition includes a therapeutically effective amount of at least one physiologically active agent or prodrug thereof, an effective amount of at least one dermal penetration enhancer; and at least one non-volatile liquid. The transdermal drug delivery composition is administered to a dermal or mucosal surface of an animal needing the same using a metered spray device capable of delivering a fine spray of substantially uniform particle size to minimize the required drying time therefor.

The invention discloses an alcohol-free fountain solution condensate. The process for preparing the alcohol-free fountain solution condensate comprises the following steps: proportionally weighing fatty alcohol-polyoxyethylene ether, coco-glucoside, Arabic gum, citric acid, sulfonylation dextrosamine, gluconic acid sodium salt, phosphoric acid and disodium hydrogen phosphate; dissolving the solid materials in water into solution, and diluting liquid materials in water; respectively putting the materials into a reaction kettle; and stirring for 30 to 45 minutes to obtain the alcohol-free fountain solution condensate. The alcohol-free fountain solution condensate does not contain alcohol or isopropanol, and can be used after being diluted by water into 2-3 percent solution. Fountain solution prepared from the alcohol-free fountain solution condensate not only ensures that the printing has high definition, vivid effect and wide application, but also has no harm to human body and no pollution to the environment. Compared with market fountain solution which consumes large amount of alcohol or isopropanol or alcohol-reduced fountain solution, the alcohol-free fountain solution condensate greatly reduces the cost.

The invention discloses an alcohol-free alkaline texturing solution for a mono-crystalline silicon wafer, a texturing method for the mono-crystalline silicon wafer, a solar cell and a manufacturing method for the solar cell. The alcohol-free alkaline texturing solution for the mono-crystalline silicon wafer comprises an alkaline solution and a texturing additive, wherein the texturing additive is an alcohol-free additive. According to the alcohol-free alkaline texturing solution, isopropanol which is harmful to human bodies and the environment adopted in the conventional alkaline texturing solution is abandoned; the corrosion depth of the surface of a silicon wafer can be controlled within the range of 5 to 7.5 mu m easily by performing surface texturing on the mono-crystalline silicon wafer obtained by performing linear cutting on a diamond by only adopting the alcohol-free alkaline texturing solution consisting of the alkaline solution and the alcohol-free additive; meanwhile, the corrosion speed is guaranteed; the anisotropy of corrosion is enhanced; pyramid structures on the surface of the silicon wafer obtained after the texturing are small and uniform in size, so that the reflectivity of the surface of the silicon wafer is reduced by about 1 percent; the light absorption capacity of the surface of the silicon wafer is increased; the conversion efficiency of the solar cell is improved.

Topical alcoholic gel compositions are disclosed that are useful for delivering therapeutic levels of an NSAID to target in and below the skin. The compositions comprise a topically active drug, an alcoholic solvent, a polymeric thickener, and optionally a keratolytic agent. In one embodiment, excellent viscosity for dermal application is attained without the need of a step for neutralizing the pH of the composition. Alcoholic and alcohol-free topical compositions comprising an NSAID prodrug are also disclosed. The compositions are particularly useful for the treatment of pseudofolliculitis barbae.

The invention discloses an alcohol-free printing fountain solution and a preparation method of the alcohol-free printing fountain solution. The alcohol-free printing fountain solution comprises, by weight, 10-15% of propylene glycol monomethyl ether, 2-4% of ethylene glycol, 4-8% of a citric acid, 0.5-1.5% of sodium hydroxide, 15-25% of glycerinum, 0.1-0.3% of sodium carboxymethyl cellulose, 0.05-0.1% of lauroyl diethanol amine, 0.4-0.6% of liquid tea saponin, 0.3-0.6% of dodecyl dimethyl benzyl ammonium chloride, 0.5-1% of dodecyl glucoside, 0.05-0.1% of 2-ethyl hexanol and 50-55% of water. The alcohol-free printing fountain solution does not contain isopropyl alcohol and is low in toxicity, safe, environmentally friendly, good in printing effect and low in cost, thereby having huge economic benefit and social benefit.

The invention discloses a method for preparing a silica aerogel composite material by adopting a chloride-free and alcohol-free process. The method comprises the following steps: S1, adopting a water-based silicon source as a raw material, regulating the pH value of sol with a chloridion-free acid, adding an additive after desalting, and uniformly stirring to obtain a first mixed solution; S2, immersing a fiber reinforced material into the first mixed solution, and completing gel curing; S3, standing the obtained composite gel material so as to obtain an aged composite gel material; S4, placing the aged composite gel material in a chloride-free and alcohol-free displacer to realize uniform solution infiltration; S5, performing surface methylsilane modification on the composite gel by usinga chloride-free surface modifier; S6, drying the modified composite gel, thereby obtaining the silica aerogel composite material. The invention provides a method for preparing the silica aerogel composite material without any chloride ion or alcohol substance in the formula.

The invention relates to a monocrystalline silicon wafer alcohol-free texturing process and a texturing additive. Firstly, a silicon wafer is placed in preprocessing liquid so as to be preprocessed for 60 s to 300 s, and the silicon wafer is then placed in texturing liquid for texturing. The monocrystalline silicon texturing process includes the steps that deionized water is heated to 70 DEG C to 90 DEG C, sodium hydroxide or potassium hydroxide is added, and monocrystalline silicon texturing corrosive liquid is acquired. When the texturing additive is adopted for texturing, isopropanol or ethyl alcohol is not needed, tiny, even and dense pyramid texturing faces can be acquired, texturing cost is reduced, and environmental pollution is avoided. The preprocessing process is added before the texturing step, the silicon wafer acquired after texturing can be cleaner, rework caused by white spot fingerprints and the like can be reduced, and certain practical value is achieved.

An alcohol-free, oral solution of nizatidine treats gastric and intestinal disorders. Oral doses of solution, which are equivalent to 150 mg twice daily, or 300 mg once daily, pill form of conventional nizatidine are orally administered and have a bioequivalency greater than 70%. The oral solution allows a wider population to obtain nizatidine treatment, particularly children, and the elderly, who have difficulty ingesting pills, can take the oral solution. Also, adolescents and younger children, in particular, can be treated with an alcohol-free oral solution.